Pharmaceuticals, Biotechnology and Life Sciences
Mylan N.V. has launch Almotriptan Tablets USP, 6.25 mg and 12.5 mg, the generic version of Janssen Pharmaceutical’s AXERT in the U.S.…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
United States Food and Drug Administration (FDA) has approved Lonsurf (trifluridine and tipiracil) tablets for the treatment of patients with metastatic colorectal cancer who have been previously…
U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
Strensiq is the first treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP) approved approved by FDA.